ENGN: חוב לטווח קצר של החברה enGene Holdings Inc.

enGene Holdings Inc. (ENGN) is developing cutting-edge gene therapy methods by collaborating with top urological and oncology centers to combat bladder cancer. The business relies on an autonomous product cycle, rendering it resilient to global crises. The current metric stands at 0.00. This chart illustrates the price action of the company's short-term debt obligations.

enGene Holdings Inc. is developing an innovative non-viral gene therapy delivery platform that requires significant capital expenditures. The total volume of liabilities maturing within one year directly reflects the issuer's current debt load. This metric measures liquidity by capturing loans due for payment within the next twelve months. By analyzing the company's short-term borrowings, an investor determines the balance between financial stability and the pace of expansion. A reduction in this indicator minimizes default risks but may limit the speed of technological growth.